Tirzepatide 40Mg Pen Device With Cartridge Box (R&D Only) Suppliers & Bulk Manufacturers
Available Forms: Prefilled syringe
Available Strengths: 40 mg
Reference Brands: Generic formulations
Category:
R&D
Tirzepatide 40mg Pen device with Cartridge Box (R&D Only) is available in Prefilled syringe
and strengths such as 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tirzepatide 40mg Pen device with Cartridge Box (R&D Only) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tirzepatide 40mg Pen device with Cartridge Box (R&D Only) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tirzepatide 40 mg is a synthetic peptide used in research and laboratory studies focused on diabetes and weight management. It acts as a dual GIP and GLP-1 receptor agonist, making it valuable for investigational studies on metabolic regulation. For research and laboratory use only.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing